Brain Metastasis Pipeline Review 2021

Report Code: PMI461121 | Publish Date: February 2021 | No. of Pages: 132

Brain Metastasis Pipeline Review 2021 Overview

Brain Metastasis- Pipeline Review

Brain metastasis is a tumor in brain. It occurs when cancer cells spread from their original site to the brain. Any type of cancer can affect brain, but the most likely types to cause brain metastases are kidney, lung, colon, breast, and melanoma. Brain metastases also known as secondary brain tumors, is present in 10 to 30 percent of adults suffering from cancer. The metastatic brain tumors grows faster and creates pressure on brain by changing the function of surrounding brain tissue. Brain metastases causes several different signs and symptoms. Treatment for the people suffering from the symptoms of brain metastases are surgery, radiation therapy or both. In most cases, immunotherapy and chemotherapy are helpful.

Treatment is usually focused on reducing symptoms and pain resulting from the cancer. According to the American Association of Neurological Surgeons, approximately 0.2 million of new cases for brain metastases are being diagnosed in the U.S annually.

Pharmaceutical companies are focusing on launching drugs to treat Brain metastasis. For instance, on September 2019, Eli Lilly and Company declared positive results for Selpercatinib (Loxo-292), representing 68 % objective response rate and sustained durability in heavily pretreated ret fusion-positive non-small cell lung cancer.

Approximately 70% of pipeline drugs for Brain Metastasis are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Brain Metastasis.

Report Description

The report on Brain Metastasis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Brain Metastasis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

  • Assessment of pipeline products based on various stages of devolvement.
  • Provides an overview of the global therapeutic landscape of Brain Metastasis (Infectious Disease).
  • Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
  • The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
  • Latest news, articles, press-release, and related conferences

Brain Metastasis Pipeline Review 2021 Key Issues Addressed

  • Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
  • Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
  • Build strategic initiatives by understanding the focus areas of leading companies
  • Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Brain Metastasis Pipeline Review 2021 Table of Contents


  1. Introduction
  • Objectives of the Study
  • Definition
  • Report Overview
  • Brain Metastasis Overview
  1. Executive Summary
  2. Brain Metastasis: Pipeline Assessment
  • Company Overview
  • Product Description
  • Status
  • Phase
  • Study Design
  • Route of Administration
  • Indication       
  • Condition        
  • NCT Number              
  • Sponsor          
  • Collaborator   
  • Brief Title         
  • Study Start Date         
  • Study completion (Estimated/Actual)
  • Study Completion Date
  • Enrollment     
  • Research Location (Listed Location Countries)
  1. Brain Metastasis: Analysis on Dormant & Discontinued Pipeline Candidates
  • Overview
  • Product Description
  • Reason for Discontinuation
  1. Brain Metastasis: Additional Key Insights
  • Epidemiology Overview: Brain Metastasis
  1. Brain Metastasis: Press Releases, Latest News and Conference Details


  • Table of Content is tentative and subject to change as the research progresses
  • The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.